Half brain irradiation in a murine model of breast cancer brain metastasis: magnetic resonance imaging and histological assessments of dose-response
Background Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain...
Saved in:
| Published in | Radiation oncology (London, England) Vol. 13; no. 1; pp. 104 - 11 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
01.06.2018
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1748-717X 1748-717X |
| DOI | 10.1186/s13014-018-1028-8 |
Cover
Loading…
| Abstract | Background
Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases’ responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations.
Methods
Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size.
Results
In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased.
Conclusions
Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. |
|---|---|
| AbstractList | Background
Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases’ responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations.
Methods
Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size.
Results
In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased.
Conclusions
Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases' responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations.BACKGROUNDBrain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases' responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations.Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size.METHODSHalf brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size.In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased.RESULTSIn the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased.Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases.CONCLUSIONSRadiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases' responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations. Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using [gamma]-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size. In the acute setting, [gamma]-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While [gamma]-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual [gamma]-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased. Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. Background Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases' responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations. Methods Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using [gamma]-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size. Results In the acute setting, [gamma]-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While [gamma]-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual [gamma]-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased. Conclusions Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. Keywords: Breast cancer, Brain metastases, Small animal radiation therapy, Radiation dose-response, Magnetic resonance imaging, DNA double-strand breaks, [gamma]-H2AX Abstract Background Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases’ responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations. Methods Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size. Results In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased. Conclusions Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases' responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations. Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size. In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased. Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. Background Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases’ responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations. Methods Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size. Results In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased. Conclusions Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases. |
| ArticleNumber | 104 |
| Audience | Academic |
| Author | Wong, Eugene Dick, Frederick A. Jensen, Michael D. Foster, Paula J. Chambers, Ann F. Murrell, Donna H. Zarghami, Niloufar |
| Author_xml | – sequence: 1 givenname: Niloufar surname: Zarghami fullname: Zarghami, Niloufar organization: Department of Medical Biophysics, University of Western Ontario – sequence: 2 givenname: Donna H. surname: Murrell fullname: Murrell, Donna H. organization: Department of Medical Biophysics, University of Western Ontario, Imaging Research Laboratories, Robarts Research Institute – sequence: 3 givenname: Michael D. surname: Jensen fullname: Jensen, Michael D. organization: Department of Medical Biophysics, University of Western Ontario – sequence: 4 givenname: Frederick A. surname: Dick fullname: Dick, Frederick A. organization: Department of Biochemistry, University of Western Ontario, London Regional Cancer Program, University of Western Ontario, Department of Oncology, University of Western Ontario – sequence: 5 givenname: Ann F. surname: Chambers fullname: Chambers, Ann F. organization: Department of Medical Biophysics, University of Western Ontario, London Regional Cancer Program, University of Western Ontario, Department of Oncology, University of Western Ontario – sequence: 6 givenname: Paula J. surname: Foster fullname: Foster, Paula J. organization: Department of Medical Biophysics, University of Western Ontario, Imaging Research Laboratories, Robarts Research Institute – sequence: 7 givenname: Eugene orcidid: 0000-0001-6869-0122 surname: Wong fullname: Wong, Eugene email: ewong4@uwo.ca organization: Department of Medical Biophysics, University of Western Ontario, London Regional Cancer Program, University of Western Ontario, Department of Oncology, University of Western Ontario, Department of Physics and Astronomy, University of Western Ontario |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29859114$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNURH_gAdggS2zYpNhJ_BMWSFUFtFIlNiCxs27sm9SjxB7sTCXegwfG6QxlpgLkha3r7xz7Xp3T4sgHj0XxktFzxpR4m1hNWVNSpkpGK1WqJ8UJk40qJZPfjvbOx8VpSitKG17T9llxXLWKt4w1J8XPKxh70kVwnrgYwTqYXchnT4BMm-g8kilYHElYMIQ0EwPeYNyJJpxzDZJL78gEg8fZGRIxBb9QxOWa8wMBb8mtS3MYw-AMjARSwpQm9HNarG1IWGbZOviEz4unPYwJX-z2s-Lrxw9fLq_Km8-fri8vbkojaD2XtrZc2qrppGKqk1VrqbB9zSxaJixF1RvZVMAoYCdlxaipW1Sd5UqAFUbWZ8X11tcGWOl1zJ-NP3QAp-8LIQ4aYu5nRN3bTiBvZM2WoTYWeikq1UqGvTId9tnr_dZrvekmtCY3FmE8MD288e5WD-FO81Ytttngzc4ghu8bTLOeXDI4juAxbJKuaNNyrlRDM_r6EboKm-jzqDLFBZdUyj1qgNyA833I75rFVF_wRiheKSEydf4XKi-LkzM5b73L9QPBq_1GHzr8nakMsC1gYkgpYv-AMKqX3OptbnXOrV5yq1XWyEca4-b7JObfuPG_ymqrTPkVP2D8M4t_i34B3kMDXw |
| CitedBy_id | crossref_primary_10_1186_s13578_020_00415_1 crossref_primary_10_1088_2057_1976_ab79f1 crossref_primary_10_3390_cancers13143416 crossref_primary_10_1016_j_ijrobp_2021_08_010 |
| Cites_doi | 10.1593/tlo.12109 10.1007/s00330-003-1957-x 10.1118/1.4933200 10.18632/aging.100025 10.1016/j.tranon.2016.04.006 10.1016/j.nurt.2009.04.012 10.1016/j.dnarep.2006.05.040 10.3109/09553002.2014.922719 10.1667/RR1851.1 10.4161/cbt.2.3.373 10.1016/j.radonc.2013.11.016 10.1088/1748-0221/8/06/C06008 10.1074/jbc.273.10.5858 10.3389/fonc.2014.00123 10.1242/jcs.03433 10.1016/j.tranon.2015.03.009 10.3109/09553002.2015.997897 10.1002/mrm.20356 10.4161/cc.5.24.3569 10.4103/2152-7806.111301 10.3390/ijms140815810 10.2174/1568009043481641 10.1667/RR2214.1 10.1118/1.4812422 10.18632/aging.100019 10.1038/sj.onc.1203902 10.1007/s10585-015-9739-9 10.1371/journal.pgen.1000170 10.1186/1471-2407-10-4 10.1359/jbmr.2001.16.8.1486 10.1097/RLI.0b013e318226c427 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2018 COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2018 – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QO 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH K9. M0S M1P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13014-018-1028-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1748-717X |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_fdb6e5473117484daf7628971ef8cbef PMC5984731 A546852866 29859114 10_1186_s13014_018_1028_8 |
| Genre | Journal Article |
| GeographicLocations | Canada |
| GeographicLocations_xml | – name: Canada |
| GrantInformation_xml | – fundername: Breast Cancer Society of Canada funderid: http://dx.doi.org/10.13039/100012172 – fundername: London Regional Cancer Program Catalyst Grant – fundername: Natural Sciences and Engineering Research Council of Canada funderid: http://dx.doi.org/10.13039/501100000038 – fundername: ; |
| GroupedDBID | --- 0R~ 123 29P 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE I-F IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QO 7XB 8FD 8FK AZQEC DWQXO FR3 K9. P64 PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-d3d57d24b7818b729d06df31ded16d0e8fc742a10aeb77210c39e8bd586ad6c73 |
| IEDL.DBID | M48 |
| ISSN | 1748-717X |
| IngestDate | Wed Aug 27 01:31:31 EDT 2025 Thu Aug 21 14:35:49 EDT 2025 Fri Sep 05 11:57:53 EDT 2025 Sat Jul 26 02:25:57 EDT 2025 Tue Jun 17 21:20:58 EDT 2025 Tue Jun 10 20:28:03 EDT 2025 Wed Feb 19 02:43:35 EST 2025 Tue Jul 01 03:39:24 EDT 2025 Thu Apr 24 23:09:52 EDT 2025 Sat Sep 06 07:29:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Small animal radiation therapy γ-H2AX Magnetic resonance imaging Breast cancer Brain metastases DNA double-strand breaks Radiation dose-response |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-d3d57d24b7818b729d06df31ded16d0e8fc742a10aeb77210c39e8bd586ad6c73 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-6869-0122 |
| OpenAccessLink | https://doi.org/10.1186/s13014-018-1028-8 |
| PMID | 29859114 |
| PQID | 2056570770 |
| PQPubID | 55355 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_fdb6e5473117484daf7628971ef8cbef pubmedcentral_primary_oai_pubmedcentral_nih_gov_5984731 proquest_miscellaneous_2049558840 proquest_journals_2056570770 gale_infotracmisc_A546852866 gale_infotracacademiconefile_A546852866 pubmed_primary_29859114 crossref_primary_10_1186_s13014_018_1028_8 crossref_citationtrail_10_1186_s13014_018_1028_8 springer_journals_10_1186_s13014_018_1028_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-01 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Radiation oncology (London, England) |
| PublicationTitleAbbrev | Radiat Oncol |
| PublicationTitleAlternate | Radiat Oncol |
| PublicationYear | 2018 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | K Thind (1028_CR21) 2014; 110 C Heyn (1028_CR39) 2005; 53 JP Banáth (1028_CR33) 2010; 10 A Ivashkevich (1028_CR29) 2013; 487 1028_CR9 CA Perez (1028_CR22) 2013 K Scheffler (1028_CR27) 2003; 13 D Smart (1028_CR3) 2015; 32 AJ Nakamura (1028_CR34) 2009; 1 1028_CR4 M Grams (1028_CR7) 2014; 90 DB Percy (1028_CR26) 2011; 46 E Ford (1028_CR8) 2016; 26 N Bhogal (1028_CR16) 2010; 173 1028_CR30 N Andratschke (1028_CR17) 2011; 31 1028_CR13 1028_CR10 1028_CR38 DH Murrell (1028_CR1) 2016; 9 1028_CR15 1028_CR37 1028_CR14 1028_CR36 N Zarghami (1028_CR6) 2015; 42 EC Ford (1028_CR28) 2011; 175 F Conley (1028_CR19) 1979; 39 K Rothkamm (1028_CR11) 2009; 45 EI Azzam (1028_CR41) 2004; 4 T Yu (1028_CR35) 2006; 5 CF Pereira (1028_CR32) 2008; 4 CM Brown (1028_CR5) 2007; 120 T Yoneda (1028_CR18) 2001; 16 1028_CR20 1028_CR40 1028_CR23 L Hernández (1028_CR31) 2013; 14 WM Bonner (1028_CR12) 2011; 8 T Ranjan (1028_CR24) 2009; 6 DH Murrell (1028_CR2) 2016; 0 1028_CR25 18773085 - PLoS Genet. 2008 Sep 05;4(9):e1000170 22198208 - Cancer Lett. 2012 Dec 31;327(1-2):123-33 23927303 - Med Phys. 2013 Aug;40(8):081706 9488723 - J Biol Chem. 1998 Mar 6;273(10):5858-68 12878854 - Cancer Biol Ther. 2003 May-Jun;2(3):233-5 24904834 - Front Oncol. 2014 May 26;4:123 23903043 - Int J Mol Sci. 2013 Jul 30;14(8):15810-26 24844370 - Int J Radiat Biol. 2014 Oct;90(10 ):936-942 26520740 - Med Phys. 2015 Nov;42(11):6507-13 26055175 - Transl Oncol. 2015 Jun;8(3):176-84 15678551 - Magn Reson Med. 2005 Feb;53(2):312-20 427739 - Cancer Res. 1979 Mar;39(3):1001-7 27554118 - Biomed Environ Sci. 2016 Jul;29(7):484-93 12928954 - Eur Radiol. 2003 Nov;13(11):2409-18 21378339 - Anticancer Res. 2011 Feb;31(2):561-4 25529973 - Int J Radiat Biol. 2015 Apr;91(4):360-7 20157510 - Aging (Albany NY). 2009 Feb 04;1(2):212-8 27267840 - Transl Oncol. 2016 Jun;9(3):219-27 22741041 - Transl Oncol. 2012 Jun;5(3):217-25 23717795 - Surg Neurol Int. 2013 May 02;4(Suppl 4):S236-44 27851873 - Magn Reson Med. 2017 Oct;78(4):1506-1512 21449714 - Radiat Res. 2011 Jun;175(6):774-83 20041754 - Radiat Res. 2010 Jan;173(1):1-9 11499871 - J Bone Miner Res. 2001 Aug;16(8):1486-95 20157507 - Aging (Albany NY). 2009 Feb 17;1(2):154-6 17502480 - J Cell Sci. 2007 May 15;120(Pt 10):1703-5 27619256 - Semin Radiat Oncol. 2016 Oct;26(4):349-55 19560748 - Neurotherapeutics. 2009 Jul;6(3):598-603 14965267 - Curr Cancer Drug Targets. 2004 Feb;4(1):53-64 19861731 - Ann Ist Super Sanita. 2009;45(3):265-71 20051134 - BMC Cancer. 2010 Jan 05;10:4 26319493 - Clin Exp Metastasis. 2015 Oct;32(7):717-27 19005492 - Nat Rev Cancer. 2008 Dec;8(12):957-67 16814620 - DNA Repair (Amst). 2006 Aug 13;5(8):935-46 24440041 - Radiother Oncol. 2014 Feb;110(2):317-22 11077445 - Oncogene. 2000 Nov 2;19(46):5281-90 17172873 - Cell Cycle. 2006 Dec;5(24):2909-13 21788908 - Invest Radiol. 2011 Nov;46(11):718-25 |
| References_xml | – volume: 45 start-page: 265 year: 2009 ident: 1028_CR11 publication-title: Ann Ist Super Sanita – ident: 1028_CR25 doi: 10.1593/tlo.12109 – volume: 13 start-page: 2409 year: 2003 ident: 1028_CR27 publication-title: Eur Radiol doi: 10.1007/s00330-003-1957-x – volume: 42 start-page: 6507 year: 2015 ident: 1028_CR6 publication-title: Med Phys [Internet] doi: 10.1118/1.4933200 – ident: 1028_CR13 doi: 10.18632/aging.100025 – volume: 9 start-page: 219 year: 2016 ident: 1028_CR1 publication-title: Transl. Oncol. [Internet]. The Authors doi: 10.1016/j.tranon.2016.04.006 – volume: 6 start-page: 598 year: 2009 ident: 1028_CR24 publication-title: Neurotherapeutics doi: 10.1016/j.nurt.2009.04.012 – volume: 5 start-page: 935 year: 2006 ident: 1028_CR35 publication-title: DNA Repair (Amst) doi: 10.1016/j.dnarep.2006.05.040 – volume: 90 start-page: 936 year: 2014 ident: 1028_CR7 publication-title: Int J Radiat Biol doi: 10.3109/09553002.2014.922719 – volume: 173 start-page: 1 year: 2010 ident: 1028_CR16 publication-title: Radiat Res doi: 10.1667/RR1851.1 – ident: 1028_CR9 doi: 10.4161/cbt.2.3.373 – volume: 110 start-page: 317 year: 2014 ident: 1028_CR21 publication-title: Radiother Oncol [Internet] Elsevier Ireland Ltd doi: 10.1016/j.radonc.2013.11.016 – ident: 1028_CR30 doi: 10.1088/1748-0221/8/06/C06008 – ident: 1028_CR10 doi: 10.1074/jbc.273.10.5858 – ident: 1028_CR36 doi: 10.3389/fonc.2014.00123 – volume: 120 start-page: 1703 year: 2007 ident: 1028_CR5 publication-title: J Cell Sci [Internet] doi: 10.1242/jcs.03433 – ident: 1028_CR40 doi: 10.1016/j.tranon.2015.03.009 – ident: 1028_CR15 doi: 10.3109/09553002.2015.997897 – volume: 487 start-page: 109 year: 2013 ident: 1028_CR29 publication-title: Cancer Lett – volume: 53 start-page: 312 year: 2005 ident: 1028_CR39 publication-title: Magn Reson Med doi: 10.1002/mrm.20356 – ident: 1028_CR38 – ident: 1028_CR14 doi: 10.4161/cc.5.24.3569 – ident: 1028_CR23 doi: 10.4103/2152-7806.111301 – volume: 14 start-page: 15810 year: 2013 ident: 1028_CR31 publication-title: Int J Mol Sci doi: 10.3390/ijms140815810 – volume: 4 start-page: 53 year: 2004 ident: 1028_CR41 publication-title: Curr Cancer Drug Targets doi: 10.2174/1568009043481641 – volume: 175 start-page: 774 year: 2011 ident: 1028_CR28 publication-title: Radiat Res doi: 10.1667/RR2214.1 – ident: 1028_CR4 doi: 10.1593/tlo.12109 – volume: 26 start-page: 349 year: 2016 ident: 1028_CR8 publication-title: Elsevier – ident: 1028_CR20 doi: 10.1118/1.4812422 – volume: 1 start-page: 212 year: 2009 ident: 1028_CR34 publication-title: Aging (Albany NY) doi: 10.18632/aging.100019 – ident: 1028_CR37 doi: 10.1038/sj.onc.1203902 – volume-title: Perez and Brady’s principles and practice of radiation oncology year: 2013 ident: 1028_CR22 – volume: 32 start-page: 717 year: 2015 ident: 1028_CR3 publication-title: Clin Exp Metastasis [Internet] Springer Netherlands doi: 10.1007/s10585-015-9739-9 – volume: 4 start-page: 1 year: 2008 ident: 1028_CR32 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1000170 – volume: 31 start-page: 561 year: 2011 ident: 1028_CR17 publication-title: Anticancer Res – volume: 39 start-page: 1001 year: 1979 ident: 1028_CR19 publication-title: Cancer Res [Internet] – volume: 8 start-page: 957 year: 2011 ident: 1028_CR12 publication-title: Cancer – volume: 0 start-page: 1 year: 2016 ident: 1028_CR2 publication-title: Magn Reson Med [Internet] – volume: 10 start-page: 1 year: 2010 ident: 1028_CR33 publication-title: BMC Cancer doi: 10.1186/1471-2407-10-4 – volume: 16 start-page: 1486 year: 2001 ident: 1028_CR18 publication-title: J Bone Miner Res doi: 10.1359/jbmr.2001.16.8.1486 – volume: 46 start-page: 718 year: 2011 ident: 1028_CR26 publication-title: Investig Radiol doi: 10.1097/RLI.0b013e318226c427 – reference: 23903043 - Int J Mol Sci. 2013 Jul 30;14(8):15810-26 – reference: 16814620 - DNA Repair (Amst). 2006 Aug 13;5(8):935-46 – reference: 27267840 - Transl Oncol. 2016 Jun;9(3):219-27 – reference: 21378339 - Anticancer Res. 2011 Feb;31(2):561-4 – reference: 24440041 - Radiother Oncol. 2014 Feb;110(2):317-22 – reference: 9488723 - J Biol Chem. 1998 Mar 6;273(10):5858-68 – reference: 23717795 - Surg Neurol Int. 2013 May 02;4(Suppl 4):S236-44 – reference: 20157510 - Aging (Albany NY). 2009 Feb 04;1(2):212-8 – reference: 26520740 - Med Phys. 2015 Nov;42(11):6507-13 – reference: 427739 - Cancer Res. 1979 Mar;39(3):1001-7 – reference: 26055175 - Transl Oncol. 2015 Jun;8(3):176-84 – reference: 19861731 - Ann Ist Super Sanita. 2009;45(3):265-71 – reference: 22198208 - Cancer Lett. 2012 Dec 31;327(1-2):123-33 – reference: 19005492 - Nat Rev Cancer. 2008 Dec;8(12):957-67 – reference: 27554118 - Biomed Environ Sci. 2016 Jul;29(7):484-93 – reference: 27851873 - Magn Reson Med. 2017 Oct;78(4):1506-1512 – reference: 12928954 - Eur Radiol. 2003 Nov;13(11):2409-18 – reference: 14965267 - Curr Cancer Drug Targets. 2004 Feb;4(1):53-64 – reference: 11077445 - Oncogene. 2000 Nov 2;19(46):5281-90 – reference: 20157507 - Aging (Albany NY). 2009 Feb 17;1(2):154-6 – reference: 27619256 - Semin Radiat Oncol. 2016 Oct;26(4):349-55 – reference: 24904834 - Front Oncol. 2014 May 26;4:123 – reference: 12878854 - Cancer Biol Ther. 2003 May-Jun;2(3):233-5 – reference: 17502480 - J Cell Sci. 2007 May 15;120(Pt 10):1703-5 – reference: 26319493 - Clin Exp Metastasis. 2015 Oct;32(7):717-27 – reference: 17172873 - Cell Cycle. 2006 Dec;5(24):2909-13 – reference: 15678551 - Magn Reson Med. 2005 Feb;53(2):312-20 – reference: 21449714 - Radiat Res. 2011 Jun;175(6):774-83 – reference: 24844370 - Int J Radiat Biol. 2014 Oct;90(10 ):936-942 – reference: 25529973 - Int J Radiat Biol. 2015 Apr;91(4):360-7 – reference: 18773085 - PLoS Genet. 2008 Sep 05;4(9):e1000170 – reference: 21788908 - Invest Radiol. 2011 Nov;46(11):718-25 – reference: 20051134 - BMC Cancer. 2010 Jan 05;10:4 – reference: 23927303 - Med Phys. 2013 Aug;40(8):081706 – reference: 20041754 - Radiat Res. 2010 Jan;173(1):1-9 – reference: 19560748 - Neurotherapeutics. 2009 Jul;6(3):598-603 – reference: 22741041 - Transl Oncol. 2012 Jun;5(3):217-25 – reference: 11499871 - J Bone Miner Res. 2001 Aug;16(8):1486-95 |
| SSID | ssj0045309 |
| Score | 2.2036433 |
| Snippet | Background
Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of... Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern... Background Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of... Abstract Background Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 104 |
| SubjectTerms | Animal models Animals Biomedical and Life Sciences Biomedicine Brain - diagnostic imaging Brain - metabolism Brain - radiation effects Brain cancer Brain damage Brain metastases Brain Neoplasms - diagnostic imaging Brain Neoplasms - radiotherapy Brain Neoplasms - secondary Brain tumors Breast cancer Breast Neoplasms - pathology Cancer Cancer metastasis Cancer Research Cancer therapies Care and treatment Cell cycle Cell Cycle - radiation effects Cell density Cell Line, Tumor Cell size Computed tomography Correlation analysis Cranial Irradiation - methods Cytokinesis Density Deoxyribonucleic acid Development and progression Disease control Disease Models, Animal Dissection DNA DNA biosynthesis DNA Breaks, Double-Stranded - radiation effects DNA damage DNA double-strand breaks Dose-Response Relationship, Radiation Drug dosages Female Fluorescence Histology Histones - metabolism Histones - radiation effects Humans Imaging Immunohistochemistry Internet Irradiation Longitudinal Studies Magnetic resonance imaging Medical imaging Metastases Metastasis Mice Mice, Nude Neuroimaging NMR Nuclear magnetic resonance Oncology Parenchyma Permeability Phosphorylation Phosphorylation - radiation effects Radiation Biology and Molecular Radiation Oncology Radiation damage Radiation dosage Radiation dose-response Radiation effects Radiation therapy Radiation Tolerance - physiology Radiology Radiotherapy Radiotherapy Dosage Radiotherapy in preclinical animal models Resonance Small animal radiation therapy Tumor cell lines Tumor cells Tumors X-Rays |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9UwFA6yB_FF1PmjOkcEQVDKkjZJU9822bgI88nB3kKapHphtx3t3X_iH-w5aW5dJ-qLj21OSpJzcnK-JvkOIW-FryTi5ByiC5GLCgCKFpLjBebaBYBcpccd3fMvanUhPl_Ky1upvvBM2EQPPA3cUesbFTBBLudIe-ltC9NX1xUPrXZNaNH7sprtwNTkg4UsWZ32MLlWRyNH5ACwGalMC53rxSoUyfp_d8m31qS75yXvbJrGtejsEXmYgkh6PDX-MbkXuifk_nnaJt8nP1b2qqUNZn-g62FA-gEcfwqPlm7w_3qgMQUO7VEM0_dQh-ofUqVN2MI7O67Hj3Rjv3V405ECMO-RniPQ9SbmNqK28zQSFicHSu3M8znip30_hnyYTuGGp-Ti7PTrp1We0i_kTrFym_vSy8oXoqlgUW8gCPdM-bbkPniuPAu6dYCrLWc2NBCjc-bKOujGS62sV64qn5G9ru_CC0JrKZQKliP7neBeAkasIW7wQTHhwMtkhO3UYVziJscUGVcmYhStzKRBAxo0qEGjM_J-rnI9EXP8TfgEdTwLIqd2fAGWZpKlmX9ZWkbeoYUYnPnQOGfTBQboInJomWPopJaFViojBwtJmLFuWbyzMZM8xmgKhhvQrKpYRt7MxVgTT8F1ob9BGYCzeLMYZJ5PJjl3qaiRiZCLjFQLY130eVnSrb9HPnFZa-x1Rj7szPpXs_44pC__x5C-Ig8KnJTxr9YB2dsON-E1BHnb5jDO559oDk04 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fi9QwEA56gvgi_r56p0QQBKWYtGmS-iKneCzC-eTBvoU0Sc-F2_Zs9_4T_-CbyWZ79sR73GaydDqTSb5M8g0hb4VXFeLkHFYXIhcKAIoWFccLzLULALlKjxndkx9ycSq-L6tl2nAb07HKXUyMgdr3DvfIAaRjgo4pxT5f_M6xahRmV1MJjbvkXqQuA39Wywlwiapkdcpkci0_jhzxA4BnJDQtdK5nc1Gk7P83MP81M908NXkjdRpnpONH5GFaStKjre0fkzuhe0Lun6Rk-VPyZ2HPW9pgDQi6GgYkIUArUPhp6Rp32QONhXBoj2JYxIc6dIIhdVqHDTyz42r8RNf2rMP7jhTgeY8kHYGu1rHCEbWdp5G2OIVRaie2zxH_2vdjyIftWdzwjJwef_v5dZGnIgy5k6zc5L70lfKFaBRM7Q0sxT2Tvi25D55Lz4JuHaBry5kNDazUOXNlHXTjKy2tl06Vz8le13dhn1AwkJTBcuTAE9xXgBRrWD34IJlwEGsywnbmMC4xlGOhjHMTkYqWZmtBAxY0aEGjM_J-6nKxpee4TfgL2ngSRGbt-KAfzkwaqKb1jQxYkJlzpFn1toXpQteKh1a7JrQZeYceYnD8w8s5m64xgIrIpGWOQEldFVrKjBzOJGHcunnzzsdMihujufbyjLyZmrEnnoXrQn-JMgBq8X4xyLzYuuSkUlEjHyEXGVEzZ53pPG_pVr8iq3hVa9Q6Ix92bn39Wv_9pC9vV-KAPChwuMVdq0OytxkuwytYxG2a13GkXgGcuEQM priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9UwEA66gvgi3re6SgRBUIpJm6Spb-vichDWJxf2LaRJqgf2tNKe_Sf7g3cmzanb9QI-tpmUTmcmmelkviHkjfCVxDg5B-9C5KKCAEULybGAuXYBQq7SY0b35KtanYovZ_IsgUVjLcz1_D3X6sPI0eeHgBdBSAud69vkjuSlinlZdbRbdIUsWZ2Sln-ctth2Ijr_72vwtU3o5gHJG1nSuPkcPyD3k9dIDycxPyS3QveI3D1JefHH5HJlz1vaYLsHuh4GxBvAD07h0tIN_lAPNPa8oT2SYb8e6lDeQ5q0CVu4Z8f1-JFu7PcOSxspROI94nEEut7EZkbUdp5GhOK0YlI7A3uO-GjfjyEfpmO34Qk5Pf787WiVp34LuVOs3Oa-9LLyhWgq2MUb8Lo9U74tuQ-eK8-Cbh0E0pYzGxpwyjlzZR1046VW1itXlU_JXtd3YZ_QWgqlguUIdye4lxAU1uAo-KCYcLCsZITtxGFcAiPHnhjnJgYlWplJggYkaFCCRmfk3Tzl54TE8S_iTyjjmRBBtOMN0C2TbNK0vlEBey9zjoiq3rawM-i64qHVrgltRt6ihhg0dXg5Z1PFArCIoFnmEJjUstBKZeRgQQkm6pbDOx0zaYkYTcEw48yqimXk9TyMM_HYWxf6C6SB-BVLiYHm2aSSM0tFjdCDXGSkWijrguflSLf-EQHEZa2R64y836n1r9f66yd9_l_UL8i9Aq0v_q86IHvb4SK8BPdt27yKhnsFl9k8eg priority: 102 providerName: Springer Nature |
| Title | Half brain irradiation in a murine model of breast cancer brain metastasis: magnetic resonance imaging and histological assessments of dose-response |
| URI | https://link.springer.com/article/10.1186/s13014-018-1028-8 https://www.ncbi.nlm.nih.gov/pubmed/29859114 https://www.proquest.com/docview/2056570770 https://www.proquest.com/docview/2049558840 https://pubmed.ncbi.nlm.nih.gov/PMC5984731 https://doaj.org/article/fdb6e5473117484daf7628971ef8cbef |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ti9QwEA73AuIX8f2q5xJBEJRqX9I0FUT2ljuWhT1EXdhvIU3Sc2G31XYP9H_4g51Ju9Wep_hp2WZSkmYmM09eniHkGTNpgjjZh-iC-SwFgCJYEuIF5kxbgFyxwR3d-TmfLthsmSz3yC69VfcBm2uhHeaTWtTrV9--fn8HBv_WGbzgr5sQcQGAYiQqjYQv9skhOCaOWGzO-k0FlsTuxAfE4MIHFLPsNjmvfcXATTk2_z_n7N-c1tUDlVd2VZ2zOrtNbnVRJh23anGH7NnyLrkx7_bR75EfU7UuaI7pIeiqrpGfAAeIwl9FN7gAb6nLkUMrFMP8PlSjftRdpY3dwjPVrJo3dKMuSrwKSQG5V8jfYelq45IfUVUa6hiNuxmWqp4ItMFXm6qxft0e07X3yeLs9NNk6nf5GXzNg3jrm9gkqYlYnoLXzyFKNwE3RRwaa0JuAisKDcBbhYGyOQTxYaDjzIrcJIIrw3UaPyAHZVXaI0KzhHFuVYj0eCw0CYDIDAILY3nANExDHgl2wyF1R16OOTTW0oEYwWU7ghJGUOIISuGRF32VLy1zx7-ET3CMe0Ek3XYPqvpCdjYsC5Nzi7maQ1QhZlQBnkRkaWgLoXNbeOQ5aohEZYXGadXdcIAuIsmWHEMnRRIJzj1yPJAEk9bD4p2OyZ1FyCjAHeogTQOPPO2LsSYekyttdYkygHfx6jHIPGxVsu9SlCFVYcg8kg6UddDnYUm5-uwIx5NMYK898nKn1r-a9ddP-ug_WvmY3IzQ5tyq1jE52NaX9gkEedt8RPbTZToih-Px7OMMfk9Oz99_gKcTPhm5hZORM-6fbBZQ_Q |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9QwDI_GTYK9IP5TGBAkEBKoomnTNEVCaINNN7Y7IbRJewtpkm4n7drR3oT4HnwOPiN2_9zoEHvb4zVOVZ8dO784tgl5wW0SI072YXfBfZ4AQJE8ZpjAnBoHkCuyGNGdTMX4gH8-jA9XyO8-FwavVfY2sTHUtjR4Rg4gHQN0QZIEH06_-9g1CqOrfQuNVi123c8fANnq9zufQL4vw3B7a__j2O-6CvhGBNHCt5GNExvyLAFflcHe0gbC5hGzzjJhAydzA3BRs0C7DLaeLDBR6mRmYym0FSaJ4L3XyCrHjNYRWd3cmn752tt-HkdB2sVOmRRva4aIBeA6llANpS8H3q9pEvCvK_jLF168p3khWNv4wO1b5Ga3eaUbrbbdJiuuuEOuT7rw_F3ya6xPcpph1wk6qyose4Byp_BT0zme6zvatN6hJZJh2yBqUO2qbtLcLeCZrmf1OzrXRwVmWNLKIVwAKjqbNz2VqC4sbQold4ab6mV90Rpfbcva-VV7-9fdIwdXIqD7ZFSUhXtIaBpzIZxmWHWPMxsDNk1hv2KdCLgB6-aRoBeHMl1NdGzNcaIabCSFaiWoQIIKJaikR14vp5y2BUEuI95EGS8JsZZ386CsjlRnGlRuM-GwBTRjWNjV6hwclEwT5nJpMpd75BVqiEKLAx9ndJc4ASxi7S61AUzKOJRCeGR9QAmWwgyHex1TnaWq1fm68sjz5TDOxNt3hSvPkAZgNGY0A82DViWXLIUpVkBk3CPJQFkHPA9HitlxU8c8TiVy7ZE3vVqff9Z__9JHlzPxjNwY70_21N7OdPcxWQtx6TVnZutktKjO3BPYQi6yp926peTbVZuKP2cNgt8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXVJ4NLWAkJCRQVDtxHIdbKayWRysOVOrNcmynrNRNqiT9J_xgZhJnIeUhcUw8jjKZ8Twy9jeEvBAuzzBPjiG6ELHIIUFRIuN4gLmwHlKu1GFF9_hELk_Fx7PsLPQ57abd7lNJcjzTgChNdX9w6apxiSt50HHMBCANRmjSRMXqJrkl0PNhtVYeTaZYZCkrQinzj9NmzmjA7P_dMv_imq5vm7xWOx1c0mKH3AmxJD0chX-X3PD1PbJ9HKrl98n3pbmoaIlNIOiqbRGFAMVA4dLQNf5m93TohEMbJMMuPtSiFrRh0tr3cM90q-4NXZvzGg88UsjPG0Tp8HS1HlocUVM7OuAWBztKzQbus8NHu6bzcTtuxvUPyOni_dejZRy6MMRWsrSPXeqy3CWizMG3lxCLOyZdlXLnHZeOeVVZSK8NZ8aXEKpzZtPCq9JlShonbZ4-JFt1U_tdQotMSOkNRxA8wV0GqWIB4YPzkgkLxiYibBKHtgGiHDtlXOghVVFSjxLUIEGNEtQqIq82Uy5HfI5_Eb9FGW8IEVp7uNG05zqsVF25UnrsyMw54qw6U4G_UEXOfaVs6auIvEQN0WgA4OWsCecYgEWE0tKHwKTKEiVlRPZnlLBw7Xx40jEdDEenE4Z1aJbnLCLPN8M4EzfD1b65QhrIavGAMdA8GlVyw1JSICAhFxHJZ8o643k-Uq--DbDiWaGQ64i8ntT652v99ZM-_i_qZ2T7y7uF_vzh5NMeuZ3gQhx-aO2Trb698k8gvuvLp8Ma_gEOlkeu |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Half+brain+irradiation+in+a+murine+model+of+breast+cancer+brain+metastasis%3A+magnetic+resonance+imaging+and+histological+assessments+of+dose-response&rft.jtitle=Radiation+oncology+%28London%2C+England%29&rft.au=Zarghami%2C+Niloufar&rft.au=Murrell%2C+Donna+H&rft.au=Jensen%2C+Michael+D&rft.au=Dick%2C+Frederick+A&rft.date=2018-06-01&rft.issn=1748-717X&rft.eissn=1748-717X&rft.volume=13&rft.issue=1&rft.spage=104&rft_id=info:doi/10.1186%2Fs13014-018-1028-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1748-717X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1748-717X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1748-717X&client=summon |